Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride

被引：0

作者：

Jens Teichert

Frank Baumann

Qi Chao

Craig Franklin

Brandy Bailey

Lothar Hennig

Karel Caca

Konrad Schoppmeyer

Ulrich Patzak

Rainer Preiss

机构：

[1] Universität Leipzig,Institut für Klinische Pharmakologie

[2] Salmedix Inc.,Institut für Organische Chemie

[3] Universität Leipzig,Medizinische Klinik und Poliklinik II

[4] Universitätsklinikum Leipzig AöR,undefined

[5] Astellas Pharma GmbH,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2007年 / 59卷

关键词：

Bendamustine; Metabolism; Cytochrome P450; Cytotoxic activity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：759 / 770

页数：11

共 50 条

[41] Characterization of stable and reactive metabolites of piperine formed on incubation with human liver microsomes
Praneetha, Pammi
Balhara, Ankit
Ladumor, Mayur K.
Singh, Dilip Kumar
Patil, Amol
Preethi, Jalvadi
Pokharkar, Sunil
Deshpande, Abhijeet Yashwantrao
Giri, Sanjeev
Singh, Saranjit
JOURNAL OF MASS SPECTROMETRY, 2019, 54 (09): : 738 - 749
[42] A phase 1 study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
Rasschaert, M.
Schrijvers, D.
Van den Brande, J.
Dyck, J.
Bosmans, J.
Merkle, K.
Vermorken, J. B.
BRITISH JOURNAL OF CANCER, 2007, 96 (11) : 1692 - 1698
[43] Identification of phase I metabolites of 3-methylindole produced by pig liver microsomes
Diaz, GJ
Skordos, KW
Yost, GS
Squires, EJ
DRUG METABOLISM AND DISPOSITION, 1999, 27 (10) : 1150 - 1156
[44] Identification of Phase I and Phase II metabolites of Guanfu base a Hydrochloride in human urine
G. J. A J. Y.
J. G. Wang
Y. C. Sun
M. S. Gu
J. H. Wu
European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28 (4) : 265 - 272
[45] Identification of Phase I and Phase II metabolites of Guanfu base A hydrochloride in human urine
A, JY
Wang, GJ
Sun, JG
Gu, YC
Wu, MS
Liu, JH
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2003, 28 (04) : 265 - 272
[46] Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer
Koester, Wolf
Heider, Andrea
Niederle, Norbert
Wilke, Hansjochen
Stamatis, Georgios
Fischer, Juergen R.
Koch, Jens A.
Stahl, Michael
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 312 - 316
[47] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
Kambhampati, Swetha
Fakhri, Bita
Ai, Weiyun Z.
Kaplan, Lawrence D.
Tuscano, Joseph M.
Wieduwilt, Matthew J.
Sudhindra, Akshay
Cavallone, Erika
Reiner, Jesika
Aoun, Charlie
Castillo, Miguel
Martinelli, Michelle
Ta, Teresa
Le, Diem
Padilla, Michelle
Crawford, Erika
Andreadis, Charalambos B.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
[48] Phase I/II study to evaluate DLT, MTD and tolerability of bendamustine in pre-treated patients with advanced; Relapsed or refractory B-CLL.
Arnaudov, G
Lissitchkov, T
Peytchev, D
Ganeva, P
Merkle, K
BLOOD, 2003, 102 (11) : 356B - 356B
[49] A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma
Budde, L. Elizabeth
Martin, Daniel B.
Philip, Mary
Shustov, Andrei R.
Gooley, Theodore
Chen, Tara L.
Libby, Edward N.
Chen, Eric Y.
Kojouri, Kiarash
Langerak, Alan
Roden, Jennifer E.
Kammerer, Britt E.
Knudsen, Nancy L.
Smith, Stephen Douglas
Press, Oliver W.
Gopal, Ajay K.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[50] Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma
Pott, C.
Belada, D.
Danesi, N.
Fingerle-Rowson, G.
Gribben, J.
Harbron, C.
Hoster, E.
Kahl, B.
Mundt, K.
Sebban, C.
Sehn, L. H.
Cheson, B. D.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 93 - 94

← 1 2 3 4 5 →